Cabozantinib llus nivolumab in adult patients with advanced or metastatic renal cell carcinoma: a retrospective, non-interventional study in a real-world cohort/GUARDIANS project
Introduction: Combinations of immune-checkpoint inhibitors (ICIs) are the standard of care (SOC) for treatment-naive metastatic renal cell carcinoma (mRCC) patients. In this multicenter study, we evaluated the RW safety and efficacy of cabozantinib plus nivolumab in mRCC patients. Methods: Data were...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
28 August 2024
|
| In: |
Cancers
Year: 2024, Jahrgang: 16, Heft: 17, Pages: 1-11 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers16172998 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/cancers16172998 Verlag, kostenfrei, Volltext: https://www.mdpi.com/2072-6694/16/17/2998 
|
| Verfasserangaben: | Thomas Hilser, Christopher Darr, Günter Niegisch, Marco Julius Schnabel, Susan Foller, Lorine Häuser, Stefanie Zschäbitz, Jonas Lewerich, Philipp Ivanyi, Katrin Schlack, Pia Paffenholz, Eveline Daetwyler, Dora Niedersüß-Beke and Viktor Grünwald |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1919438815 | ||
| 003 | DE-627 | ||
| 005 | 20250717000125.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250310s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers16172998 |2 doi | |
| 035 | |a (DE-627)1919438815 | ||
| 035 | |a (DE-599)KXP1919438815 | ||
| 035 | |a (OCoLC)1528019211 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hilser, Thomas Klaus Joseph Wilhelm |d 1987- |e VerfasserIn |0 (DE-588)1237432227 |0 (DE-627)1764144457 |4 aut | |
| 245 | 1 | 0 | |a Cabozantinib llus nivolumab in adult patients with advanced or metastatic renal cell carcinoma |b a retrospective, non-interventional study in a real-world cohort/GUARDIANS project |c Thomas Hilser, Christopher Darr, Günter Niegisch, Marco Julius Schnabel, Susan Foller, Lorine Häuser, Stefanie Zschäbitz, Jonas Lewerich, Philipp Ivanyi, Katrin Schlack, Pia Paffenholz, Eveline Daetwyler, Dora Niedersüß-Beke and Viktor Grünwald |
| 264 | 1 | |c 28 August 2024 | |
| 300 | |b Diagramme | ||
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.03.2025 | ||
| 520 | |a Introduction: Combinations of immune-checkpoint inhibitors (ICIs) are the standard of care (SOC) for treatment-naive metastatic renal cell carcinoma (mRCC) patients. In this multicenter study, we evaluated the RW safety and efficacy of cabozantinib plus nivolumab in mRCC patients. Methods: Data were retrospectively collected from twelve cancer centers in Germany, Switzerland, and Austria. Patients with advanced or mRCC were eligible. The investigator-based objective response rate (ORR) and progression free survival (PFS) were calculated from the start of the treatment to progression or death. Descriptive statistics and Kaplan-Meier (KM) plots were utilized where appropriate. Results: In total, 96 eligible patients (66.6% male) with a median age of 66.0 years were included. The most common histology was clear-cell RCC (ccRCC) in 63.4% (n = 61). A prior nephrectomy was performed in 60.4% (n = 58). ECOG 0-1 was 68.8% (n = 66). A partial response was documented in 43.8% of patients (n = 42), a stable disease in 32.3% (n = 31), and a progressive disease in 8.3% (n = 8) as the best overall response. Response data were not evaluable in 13.5% (n = 13). The median follow-up time was 12.7 months (95% CI, 10.0-15.3). The PFS rate at 6 months was 89.8% in the overall population (86.8% for ccRCC; 90.0% for non-ccRCC). Adverse events (AEs) were reported in 82.3% (n = 79) for all grades and 41.7% (n = 40) for grades 3-5. Elevated liver enzymes (34.4%), diarrhea (31.3%), and hand-foot syndrome (29.2%) were the three most frequent AEs of any grade and causality. Discussion/Conclusions: In this real-world cohort of mRCC patients, the application of cabozantinib plus nivolumab was shown to be safe and feasible. Our data support the use of cabozantinib plus nivolumab as a first-line standard therapy in mRCC patients. Major limitations were the retrospective data capture and short follow-up time of our study. | ||
| 650 | 4 | |a cabozantinib | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a metastatic renal cell carcinoma | |
| 650 | 4 | |a real-world data | |
| 700 | 1 | |a Darr, Christopher |e VerfasserIn |0 (DE-588)1302614649 |0 (DE-627)1859711146 |4 aut | |
| 700 | 1 | |a Niegisch, Günter |d 1979- |e VerfasserIn |0 (DE-588)132089599 |0 (DE-627)517888394 |0 (DE-576)29893812X |4 aut | |
| 700 | 1 | |a Schnabel, Marco Julius |d 1985- |e VerfasserIn |0 (DE-588)1042767491 |0 (DE-627)769646298 |0 (DE-576)394205561 |4 aut | |
| 700 | 1 | |a Foller, Susan |e VerfasserIn |0 (DE-588)1270828711 |0 (DE-627)1819620662 |4 aut | |
| 700 | 1 | |a Häuser, Lorine |d 1989- |e VerfasserIn |0 (DE-588)1124562397 |0 (DE-627)878761667 |0 (DE-576)482834102 |4 aut | |
| 700 | 1 | |a Zschäbitz, Stefanie |d 1983- |e VerfasserIn |0 (DE-588)1037698827 |0 (DE-627)75589894X |0 (DE-576)391727206 |4 aut | |
| 700 | 1 | |a Lewerich, Jonas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ivanyi, Philipp |d 1975- |e VerfasserIn |0 (DE-588)132988445 |0 (DE-627)529572036 |0 (DE-576)299547809 |4 aut | |
| 700 | 1 | |a Schlack, Katrin |d 1981- |e VerfasserIn |0 (DE-588)1128924323 |0 (DE-627)883739259 |0 (DE-576)486137538 |4 aut | |
| 700 | 1 | |a Paffenholz, Pia Valerie |d 1988- |e VerfasserIn |0 (DE-588)1058240714 |0 (DE-627)796643016 |0 (DE-576)41428013X |4 aut | |
| 700 | 1 | |a Daetwyler, Eveline |e VerfasserIn |4 aut | |
| 700 | 1 | |a Niedersüß-Beke, Dora |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grünwald, Viktor |d 1969- |e VerfasserIn |0 (DE-588)120448475 |0 (DE-627)080680771 |0 (DE-576)292223684 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 16(2024), 17, Artikel-ID 2998, Seite 1-11 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a Cabozantinib llus nivolumab in adult patients with advanced or metastatic renal cell carcinoma a retrospective, non-interventional study in a real-world cohort/GUARDIANS project |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:17 |g elocationid:2998 |g pages:1-11 |g extent:11 |a Cabozantinib llus nivolumab in adult patients with advanced or metastatic renal cell carcinoma a retrospective, non-interventional study in a real-world cohort/GUARDIANS project |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers16172998 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/16/17/2998 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250310 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1037698827 |a Zschäbitz, Stefanie |m 1037698827:Zschäbitz, Stefanie |d 910000 |d 910100 |d 50000 |e 910000PZ1037698827 |e 910100PZ1037698827 |e 50000PZ1037698827 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 7 | ||
| 999 | |a KXP-PPN1919438815 |e 4685743326 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"28 August 2024","dateIssuedKey":"2024"}],"name":{"displayForm":["Thomas Hilser, Christopher Darr, Günter Niegisch, Marco Julius Schnabel, Susan Foller, Lorine Häuser, Stefanie Zschäbitz, Jonas Lewerich, Philipp Ivanyi, Katrin Schlack, Pia Paffenholz, Eveline Daetwyler, Dora Niedersüß-Beke and Viktor Grünwald"]},"recId":"1919438815","person":[{"family":"Hilser","display":"Hilser, Thomas Klaus Joseph Wilhelm","given":"Thomas Klaus Joseph Wilhelm","role":"aut"},{"family":"Darr","display":"Darr, Christopher","given":"Christopher","role":"aut"},{"family":"Niegisch","display":"Niegisch, Günter","given":"Günter","role":"aut"},{"role":"aut","family":"Schnabel","given":"Marco Julius","display":"Schnabel, Marco Julius"},{"family":"Foller","given":"Susan","display":"Foller, Susan","role":"aut"},{"given":"Lorine","display":"Häuser, Lorine","family":"Häuser","role":"aut"},{"display":"Zschäbitz, Stefanie","given":"Stefanie","family":"Zschäbitz","role":"aut"},{"role":"aut","family":"Lewerich","display":"Lewerich, Jonas","given":"Jonas"},{"role":"aut","family":"Ivanyi","given":"Philipp","display":"Ivanyi, Philipp"},{"family":"Schlack","given":"Katrin","display":"Schlack, Katrin","role":"aut"},{"role":"aut","given":"Pia Valerie","display":"Paffenholz, Pia Valerie","family":"Paffenholz"},{"role":"aut","family":"Daetwyler","given":"Eveline","display":"Daetwyler, Eveline"},{"role":"aut","given":"Dora","display":"Niedersüß-Beke, Dora","family":"Niedersüß-Beke"},{"role":"aut","display":"Grünwald, Viktor","given":"Viktor","family":"Grünwald"}],"title":[{"subtitle":"a retrospective, non-interventional study in a real-world cohort/GUARDIANS project","title_sort":"Cabozantinib llus nivolumab in adult patients with advanced or metastatic renal cell carcinoma","title":"Cabozantinib llus nivolumab in adult patients with advanced or metastatic renal cell carcinoma"}],"language":["eng"],"id":{"doi":["10.3390/cancers16172998"],"eki":["1919438815"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"noteIll":"Diagramme","extent":"11 S."}],"note":["Gesehen am 10.03.2025"],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2527080-1"],"issn":["2072-6694"],"eki":["614095670"]},"part":{"pages":"1-11","year":"2024","volume":"16","text":"16(2024), 17, Artikel-ID 2998, Seite 1-11","issue":"17","extent":"11"},"note":["Gesehen am 27.05.2020"],"origin":[{"dateIssuedKey":"2009","publisherPlace":"Basel","publisher":"MDPI","dateIssuedDisp":"2009-"}],"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"title":[{"title":"Cancers","title_sort":"Cancers"}],"pubHistory":["1.2009 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Cabozantinib llus nivolumab in adult patients with advanced or metastatic renal cell carcinoma a retrospective, non-interventional study in a real-world cohort/GUARDIANS projectCancers","recId":"614095670","language":["eng"]}]} | ||
| SRT | |a HILSERTHOMCABOZANTIN2820 | ||